A conference presentation at Optometry’s Meeting 2026 examined teleretina adoption in primary care settings and the expanding role of AI-assisted retinal imaging, including autonomous diabetic retinopathy detection and emerging oculomics applications, while cautioning clinicians about AI bias and the limits of consumer-facing large language models.

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

Inconsistent cataract biometry measurements most commonly reflect ocular surface instability, subtle corneal pathology, or suboptimal measurement conditions rather than random error, and a systematic diagnostic approach before repeating scans can meaningfully improve refractive predictability.

AREDS2 remains the evidence-based standard for AMD supplementation, but expanding understanding of complement dysregulation, mitochondrial dysfunction, and macular carotenoid biology has prompted discussion about whether a next-generation formulation could address pathways the current one does not target.

Primary trabeculectomy reduced the rate of visual field loss by approximately 50% compared with a medications-first approach in newly diagnosed advanced open-angle glaucoma patients across a 5-year randomized trial, though standard quality-of-life instruments failed to detect that clinical benefit.

Erucamide, a naturally occurring lipid molecule, declined as photoreceptors deteriorated in preclinical retinal degeneration models, and restoring it via nanoparticle delivery slowed aspects of tissue breakdown without reversing damage.